WO2000028982A3 - Increasing bone strength with selected bisphosphonates - Google Patents

Increasing bone strength with selected bisphosphonates Download PDF

Info

Publication number
WO2000028982A3
WO2000028982A3 PCT/US1999/027528 US9927528W WO0028982A3 WO 2000028982 A3 WO2000028982 A3 WO 2000028982A3 US 9927528 W US9927528 W US 9927528W WO 0028982 A3 WO0028982 A3 WO 0028982A3
Authority
WO
WIPO (PCT)
Prior art keywords
increase
bone strength
bone
osteocytes
bisphosphonate
Prior art date
Application number
PCT/US1999/027528
Other languages
French (fr)
Other versions
WO2000028982A2 (en
Inventor
Stavros C Manolagas
Teresita Bellido
Original Assignee
Univ Arkansas
Gador Sa
Stavros C Manolagas
Teresita Bellido
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, Gador Sa, Stavros C Manolagas, Teresita Bellido filed Critical Univ Arkansas
Priority to AU15257/00A priority Critical patent/AU1525700A/en
Publication of WO2000028982A2 publication Critical patent/WO2000028982A2/en
Publication of WO2000028982A3 publication Critical patent/WO2000028982A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/16—Phosphorus containing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/16—Phosphorus containing
    • Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing

Abstract

The present invention is a method and composition to increase bone strength in a manner that decreases fracture incidence, which may or may not include increasing bone mineral density ('BMD'). The invention includes administering an effective amount of a bisphosphonate to a host in need thereof to increase bone strength, which inhibits the apoptosis of osteoblasts and osteocytes, via activation of the extracelluar signal regulated kinases (ERK), without a significant effect on osteoclasts. In one embodiment, the bisphosphonate is not 1-amino-3-(N,N-dimethylamino)-propyliden-1,1-bisphosphonic acid or its pharmaceutically acceptable salt. An increase in osteoblast life span can lead to an increase in bone mass, i.e., an anabolic effect. Preservation of osteocyte life span can increase bone strength, which may be disproportional to the increase in bone mass. Moreover methods for screening compounds inhibiting or preventing apoptosis in osteoblasts or osteocytes, thereby enhancing bone strength, are provided.
PCT/US1999/027528 1998-11-19 1999-11-19 Increasing bone strength with selected bisphosphonates WO2000028982A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15257/00A AU1525700A (en) 1998-11-19 1999-11-19 Increasing bone strength with selected bisphosphonates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10923798P 1998-11-19 1998-11-19
US60/109,237 1998-11-19
US16548099P 1999-11-15 1999-11-15
US60/165,480 1999-11-15

Publications (2)

Publication Number Publication Date
WO2000028982A2 WO2000028982A2 (en) 2000-05-25
WO2000028982A3 true WO2000028982A3 (en) 2002-07-11

Family

ID=26806782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027528 WO2000028982A2 (en) 1998-11-19 1999-11-19 Increasing bone strength with selected bisphosphonates

Country Status (3)

Country Link
US (1) US6416737B1 (en)
AU (1) AU1525700A (en)
WO (1) WO2000028982A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1178810E (en) * 1999-05-21 2005-08-31 Novartis Ag USES OF BISPHOSPHONIC ACIDS FOR THE TREATMENT OF ANGIOGENESE
US20040097996A1 (en) 1999-10-05 2004-05-20 Omnisonics Medical Technologies, Inc. Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
EP1326630B1 (en) * 2000-09-18 2008-05-28 Sanos Bioscience A/S Use of glp-2 peptides
DE60128141T2 (en) * 2000-10-17 2008-01-03 Maria-Grazia Santa Monica Ascenzi SYSTEM AND METHOD FOR MODELING BONE STRUCTURES
US7127383B2 (en) * 2001-01-31 2006-10-24 Maria-Grazia Ascenzi Modeling viscoelastic torsional properties of osteons
GB0102480D0 (en) * 2001-01-31 2001-03-14 Cyclacel Ltd Marker
US7212958B2 (en) * 2001-10-17 2007-05-01 Maria-Grazia Ascenzi Method and system for modelling bone structure
US7353153B2 (en) * 2001-10-17 2008-04-01 Maria-Grazia Ascenzi Method and system for modeling bone structure
US7283940B2 (en) * 2001-10-17 2007-10-16 Maria-Grazia Ascenzi Multidirectional morphology and mechanics of osteonic lamellae
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
CA2470495A1 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
GR1004274B (en) * 2002-07-16 2003-06-23 Medexis ���� Steroid-protein conjugates: new compounds for the selective identification and elimination of tumor cells derived from solid cancers and hematological malignancies
MXPA05000615A (en) * 2002-07-16 2005-11-17 Medexis S A Steroid conjugates, preparation thereof and the use thereof.
WO2005000858A2 (en) * 2003-06-27 2005-01-06 Akira Odani Bisphosphonate complexes
US20050014676A1 (en) * 2003-07-15 2005-01-20 Boston Biomedical Research Institute Methods for delaying or inducing labor
MXPA06003063A (en) * 2003-09-19 2006-05-31 Pfizer Prod Inc Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate.
US7794414B2 (en) 2004-02-09 2010-09-14 Emigrant Bank, N.A. Apparatus and method for an ultrasonic medical device operating in torsional and transverse modes
CA2562132A1 (en) * 2004-04-08 2005-10-27 Merck & Co., Inc. 17 beta-acetamide-4-azasteroids as androgen receptor modulators
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
WO2006037107A2 (en) * 2004-09-28 2006-04-06 The Board Of Trustees Of The Universtity Of Arkansas Methods of identifying glucocorticoids without the detrimental side effects of bone loss
US20060100547A1 (en) * 2004-10-27 2006-05-11 Omnisonics Medical Technologies, Inc. Apparatus and method for using an ultrasonic medical device to reinforce bone
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
PE20070360A1 (en) * 2005-09-01 2007-04-19 Novartis Ag LIPOSOME COMPOSITIONS
EP2010074A4 (en) 2006-04-26 2012-08-29 Illuminoss Medical Inc Apparatus and methods for reinforcing bone
US7806900B2 (en) 2006-04-26 2010-10-05 Illuminoss Medical, Inc. Apparatus and methods for delivery of reinforcing materials to bone
AU2007322320B2 (en) 2006-11-10 2013-02-14 Illuminoss Medical, Inc. Systems and methods for internal bone fixation
US7879041B2 (en) * 2006-11-10 2011-02-01 Illuminoss Medical, Inc. Systems and methods for internal bone fixation
WO2008059059A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
MX2009001271A (en) * 2006-11-21 2009-02-11 Teikoku Pharma Usa Inc Biphosphonate inhalant formulations and methods for using the same.
WO2009059090A1 (en) 2007-10-31 2009-05-07 Illuminoss Medical, Inc. Light source
US8403968B2 (en) 2007-12-26 2013-03-26 Illuminoss Medical, Inc. Apparatus and methods for repairing craniomaxillofacial bones using customized bone plates
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
US8210729B2 (en) 2009-04-06 2012-07-03 Illuminoss Medical, Inc. Attachment system for light-conducting fibers
US8512338B2 (en) 2009-04-07 2013-08-20 Illuminoss Medical, Inc. Photodynamic bone stabilization systems and methods for reinforcing bone
US8870965B2 (en) 2009-08-19 2014-10-28 Illuminoss Medical, Inc. Devices and methods for bone alignment, stabilization and distraction
DE102009039587A1 (en) * 2009-09-01 2011-03-10 Bayer Animal Health Gmbh New combination
US8684965B2 (en) 2010-06-21 2014-04-01 Illuminoss Medical, Inc. Photodynamic bone stabilization and drug delivery systems
WO2012088432A1 (en) 2010-12-22 2012-06-28 Illuminoss Medical, Inc. Systems and methods for treating conditions and diseases of the spine
US9144442B2 (en) 2011-07-19 2015-09-29 Illuminoss Medical, Inc. Photodynamic articular joint implants and methods of use
WO2013059609A1 (en) 2011-10-19 2013-04-25 Illuminoss Medical, Inc. Systems and methods for joint stabilization
US8939977B2 (en) 2012-07-10 2015-01-27 Illuminoss Medical, Inc. Systems and methods for separating bone fixation devices from introducer
US9687281B2 (en) 2012-12-20 2017-06-27 Illuminoss Medical, Inc. Distal tip for bone fixation devices
DK2976359T4 (en) 2013-03-20 2022-06-13 Genzyme Corp PROCEDURES FOR THE TREATMENT OF OSTEOGENESIS IMPERFECTA
US10072032B2 (en) * 2016-09-19 2018-09-11 Afton Chemical Corporation AminoBisPhosphonate antiwear additives
EP3541474A4 (en) * 2016-11-16 2020-08-05 University Of Maryland, Baltimore Methods for treating bone-related disorders
EP3813696A4 (en) 2018-06-27 2022-04-13 IlluminOss Medical, Inc. Systems and methods for bone stabilization and fixation

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870063A (en) * 1985-12-12 1989-09-26 Leo Pharmaceutical Products Ltd. A/S Bisphosphonic acid derivatives, their production and use
EP0381296A1 (en) * 1984-04-30 1990-08-08 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
WO1994000129A1 (en) * 1992-06-30 1994-01-06 Procter & Gamble Pharmaceuticals, Inc. Use of phosphonates for the treatment of osteoporosis
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
WO1995011029A1 (en) * 1993-10-19 1995-04-27 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
JPH07330613A (en) * 1994-06-02 1995-12-19 Teijin Ltd Osteogenesis stimulating agent
WO1996019998A1 (en) * 1994-12-28 1996-07-04 Gador S.A. Bone mass anabolic composition comprising olpadronate
WO1996025165A1 (en) * 1995-02-17 1996-08-22 Merck & Co., Inc. Method of lessening the risk of non-vertebral bone fractures
WO1996025166A1 (en) * 1995-02-17 1996-08-22 Merck & Co., Inc. Method of lessening the risk of vertebral fractures
WO1997002827A1 (en) * 1995-07-10 1997-01-30 Gador S.A. Therapeutic use of 1-amino-3-(n,n-dimethylamino)-propyliden-1,1-bisphosphonic acid and its salts
WO1998023274A1 (en) * 1996-11-25 1998-06-04 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
US5885973A (en) * 1995-12-27 1999-03-23 Gador, S.A. Bone mass anabolic composition comprising olpadronate

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4588716A (en) 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
US4619920A (en) 1985-09-16 1986-10-28 Wisconsin Alumni Research Foundation 26,26,26,27,27-pentafluoro-1α-hydroxy-27-methoxyvitamin D3
US4870054A (en) 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
US4710382A (en) 1985-09-27 1987-12-01 Recker Robert R Treatment for osteoporosis using hGRF(1-40)NH2
AU6898287A (en) 1986-01-30 1987-08-25 University Of Utah, The Treatment of bone loss
US4833125A (en) 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US5001118A (en) 1986-12-29 1991-03-19 Kureha Kagaku Kogyo Kabushiki Kaisha Method for preventing senescence and increasing bone mass
US4970237A (en) 1987-03-20 1990-11-13 Yale University Use of clomiphene to increase bone mass in premenopausal women
US5104864A (en) 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US4973584A (en) 1989-03-09 1990-11-27 Deluca Hector F Novel 1α-hydroxyvitamin D2 epimer and derivatives
SE8903529D0 (en) 1989-10-24 1989-10-24 M Hersloef MEDICAL USE
US5071655A (en) 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
US5260290A (en) 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
CA2096350C (en) 1990-11-26 2001-10-16 Robert R. Recker Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5674844A (en) 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical Remedy for osteoporosis and diazepine compound.
EP0652975B1 (en) 1992-07-31 2004-10-13 Garvan Institute Of Medical Research Assessment of trans-acting factors allelic variation
FR2705235B1 (en) 1993-05-13 1995-07-13 Inoteb Use of particles of a biocompatible and bioresorbable calcium salt as an active ingredient in the preparation of a medicament for the local treatment of demineralizing bone diseases.
ATE203544T1 (en) 1993-05-18 2001-08-15 Ltt Inst Co Ltd OSTEOGENesis promoters and anti-osteoporosis agents
TW303299B (en) 1993-07-22 1997-04-21 Lilly Co Eli
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US5859001A (en) 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
WO1995026719A1 (en) 1994-04-01 1995-10-12 Arcturus Pharmaceutical Corporation Method for delivering biologically active materials using a thioester or thioether prodrug
GB2294879A (en) 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
AT406337B8 (en) * 1995-07-11 2000-07-25 Rosenbauer Int Ag FIREFIGHTER VEHICLE, IN PARTICULAR AIRPORT EXTINGUISHER VEHICLE, WITH AT LEAST TWO DRIVE ENGINES ARRANGED ON EACH SIDE AXLE
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
EP0977578B1 (en) 1997-01-16 2004-03-31 University Of Florida Research Foundation, Inc. Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants
US6015801A (en) 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381296A1 (en) * 1984-04-30 1990-08-08 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
US4870063A (en) * 1985-12-12 1989-09-26 Leo Pharmaceutical Products Ltd. A/S Bisphosphonic acid derivatives, their production and use
WO1994000129A1 (en) * 1992-06-30 1994-01-06 Procter & Gamble Pharmaceuticals, Inc. Use of phosphonates for the treatment of osteoporosis
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
WO1995011029A1 (en) * 1993-10-19 1995-04-27 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
JPH07330613A (en) * 1994-06-02 1995-12-19 Teijin Ltd Osteogenesis stimulating agent
WO1996019998A1 (en) * 1994-12-28 1996-07-04 Gador S.A. Bone mass anabolic composition comprising olpadronate
WO1996025165A1 (en) * 1995-02-17 1996-08-22 Merck & Co., Inc. Method of lessening the risk of non-vertebral bone fractures
WO1996025166A1 (en) * 1995-02-17 1996-08-22 Merck & Co., Inc. Method of lessening the risk of vertebral fractures
WO1997002827A1 (en) * 1995-07-10 1997-01-30 Gador S.A. Therapeutic use of 1-amino-3-(n,n-dimethylamino)-propyliden-1,1-bisphosphonic acid and its salts
US5885973A (en) * 1995-12-27 1999-03-23 Gador, S.A. Bone mass anabolic composition comprising olpadronate
WO1998023274A1 (en) * 1996-11-25 1998-06-04 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
BALENA R ET AL: "THE EFFECTS OF 2-YEAR TREATMENT WITH THE AMINOBISPHOSPHONATE ALENDRONATE ON BONE METABOLISM, BONE HISTOMORPHOMETRY, AND BONE STRENGTH IN OVARIECTOMIZED NONHUMAN PRIMATES", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 92, no. 6, 1993, pages 2577 - 2586, XP000913876, ISSN: 0021-9738 *
BELIDO T, ET AL.: "PTH PREVENTS GLUCOCORTICOLD-INDUCED APOPTOSIS OF OSTERBLAST AND OSTEOCYTES IN VITRO:DIRECT INTERFERENCE WITH A PRIVATE DEATH PATWAY UPSTREAM FROM CASPASE-3", ASMBR-IBMS JOINT MEETING, XX, XX, vol. 23, no. 05, 1 November 1998 (1998-11-01), XX, pages S518, XP002925694 *
BLACK, D. M._CUMMINGS, S. R._KARPF, D. B._CAULEY, J. A._ENSRUD, K. E._ET AL: "RANDOMIZED TRIAL OF EFFECT OF ALENDRONATE ON RISK OF #FRACTURE# IN WOMEN WITH EXISTING VERTEBRAL #FRACTURES#", LANCET, vol. 348, 7 December 1996 (1996-12-07), pages 1535 - 1541, XP000891948 *
BONE (ASMBR-IBMS SECOND JOINT MEETING) vol.23(SUPP), no. 5, November 1998, page PAGE S518, SEE ABSTRACT NUMBER F458 *
BONUCCI E. ET AL: "Does apoptosis play a role in bone remodeling?", ITALIAN JOURNAL OF MINERAL AND ELECTROLYTE METABOLISM_(_ITAL J. MINER. ELECTROLYTE METAB._), 12/1 (1-4), Italy, XP000905159 *
COINTRY, G. R. ET AL: "Intravenous olpadronate restores ovariectomy-affected bone strength. A mechanical, densitometric and tomographic (pQCT) study.", BONE, 1995, 17, 373S-8S, XP000904971 *
CUMMINGS S R ET AL: "CHANGES IN BMD SUBSTANTIALLY UNDERESTIMATE THE ANTI-FRACTURE EFFECTS OF ALENDRONATE AND OTHER ANTIRESORPTIVE DRUGS", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 11, 1996, pages S102, XP000913875, ISSN: 0884-0431 *
DATABASE MEDLINE XP002176442 *
DATABASE WPI Week 199608, Derwent World Patents Index; AN 1996-074761, XP002176443 *
DUNSTAN ET AL.: "Bone death in hip fracture in the elderly", CALCIFIED TISSUE INTERNATIONAL, vol. 47, no. 5, November 1990 (1990-11-01), pages 270 - 275 *
EASTELL R: "MANAGEMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS", JOURNAL OF INTERNAL MEDICINE, OXFORD, GB, vol. 237, no. 5, May 1995 (1995-05-01), pages 439 - 447, XP000904965, ISSN: 0954-6820 *
ENSRUD, KRISTINE E. ET AL: "Treatment with alendronate prevents fractures in women at highest risk. Results from the fracture intervention trial", ARCH. INTERN. MED., DEC. 1997, 157, 2617-2624, XP000904917 *
GIULIANI, N. ET AL: "Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo", BONE (N. Y.), 1998, 22, 455-461, XP000904866 *
HILL P A, TUMBER A, MEIKLE M C: "MULTIPLE EXTRACELLULAR SIGNALS PROMOTE OSTEOBLAST SURVIVAL AND APOPTOSIS", ENDOCRINOLOGY, THE ENDOCRINE SOCIETY, US, vol. 138, no. 09, 1 January 1997 (1997-01-01), US, pages 3849 - 3858, XP002925687, ISSN: 0013-7227, DOI: 10.1210/en.138.9.3849 *
HUGHES D E ET AL: "APOPTOSIS IN BON PHYSIOLOGY AND DISEASE", MP. MOLECULAR PATHOLOGY, BMJ PUBLISHING GROUP, LONDON, GB, vol. 50, 1997, pages 132 - 137, XP000904969 *
JILKA R L, ET AL.: "OSTEOBLAST PROGRAMMED CELL DEATH (APOPTOSIS): MODULATION BY GROWTH FACTORS AND CYTOKINES", JOURNAL OF BONE AND MINERAL RESEARCH, BLACKWELL SCIENCE, INC., US, vol. 13, no. 05, 1 January 1998 (1998-01-01), US, pages 793 - 802, XP002925689, ISSN: 0884-0431, DOI: 10.1359/jbmr.1998.13.5.793 *
JOURNAL OF CLINICAL INVESTIGATION vol. 102 no. 2, July 1998, pages 274 - 282 *
LIBERMAN, U. A._WEISS, S. R._BROLL, J._MINNE, H. W._KARPF, D. B._ET AL: "EFFECT OF ORAL ALENDRONATE ON BONE MINERAL DENSITY AND THE INCIDENCE OF #FRACTURES# IN POSTMENOPAUSAL OSTEOPOROSIS", NEW ENGLAND J. MED., vol. 333, no. 30, 30 November 1995 (1995-11-30), pages 1437 - 1443, XP000904845 *
LOURWOOD D L: "THE PHARMACOLOGY AND THERAPEUTIC UTILITY OF BISPHOSPHONATES", PHARMACOTHERAPY, BOSTON, US, vol. 18, no. 4, 1998, pages 779 - 789, XP000904953, ISSN: 0277-0008 *
MANOLAGAS S C, WEINSTEIN R S: "NEW DEVELOPMENT IN THE PATHOGENESIS AND TREATMENT OF STEROID-INDUCED OSTEOPOROSIS", JOURNAL OF BONE AND MINERAL RESEARCH, BLACKWELL SCIENCE, INC., US, vol. 14, no. 07, 1 January 1999 (1999-01-01), US, pages 1061 - 1066, XP002925686, ISSN: 0884-0431, DOI: 10.1359/jbmr.1999.14.7.1061 *
MATHOV I_(A): "#ERKs# and calcium channels are involved in the proliferative effect of bisphosphonates in osteoblastic cells in vitro.", JOURNAL OF BONE AND MINERAL RESEARCH, 1999, XP000905212 *
OHNISHI, H. ET AL: "Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats", BONE (N. Y.), OCT. 1997, 21, 335-343, XP000904946 *
PLOTKIN L I ET AL: "BISPHOSPHONATES PREVENT GLUCOCORTICOID-INDUCED APOPTOSIS OF OSTEOCYTES IN VITRO: A PUTATIVE MECHANISM INFLUENCING MECHANOSENSING", BONE, PERGAMON PRESS., OXFORD, GB, vol. 23, 1998, pages S157, XP001024016, ISSN: 8756-3282 *
PLOTKIN L.I AND AL.: "Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin", J. CLIN. INVEST., vol. 104, no. 10, November 1999 (1999-11-01), pages 1363 - 1374, XP002176441 *
RODAN G.A. ET AL: "Bisphosphonates: Mechanisms of action", JOURNAL OF CLINICAL INVESTIGATION_(_J. CLIN. INVEST._), 97/12 (2692-2696), United States, XP000904860 *
SAHNI M ET AL: "BISPHOSPHONATES ACT ON RAT BONE RESORPTION THROUGH THE MEDIATION OF OSTEOBLASTS", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 91, no. 5, May 1993 (1993-05-01), pages 2004 - 2011, XP000892358, ISSN: 0021-9738 *
TOMKINSON A, ET AL.: "THE ROLE OF ESTROGEN IN THE CONTROL OF RAT OSTEOCYTE APOPTOSIS", JOURNAL OF BONE AND MINERAL RESEARCH, BLACKWELL SCIENCE, INC., US, vol. 13, no. 08, 1 January 1998 (1998-01-01), US, pages 1243 - 1250, XP002925688, ISSN: 0884-0431, DOI: 10.1359/jbmr.1998.13.8.1243 *
TSUCHIMOTO, MASAHIRO ET AL: "Alendronate modulates osteogenesis of human osteoblastic cells in vitro", JPN. J. PHARMACOL., 1994, 66, 25-33, XP000904954 *
VAN STAA T P: "Use of cyclical etidronate and prevention of non-vertebral #fractures#.", BRITISH JOURNAL OF RHEUMATOLOGY, vol. 37, no. 1, January 1998 (1998-01-01), pages 87 - 94, XP000904862 *
VITTE C ET AL: "BISPHOSPHONATES INDUCE OSTEOBLASTS TO SECRETE AN INHIBITOR OF OSTEOCLAST-MEDIATED RESORPTION", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 137, no. 6, 1 June 1996 (1996-06-01), pages 2324 - 2333, XP002068196, ISSN: 0013-7227 *
WEINSTEIN R S, ET AL.: "INHIBITION OF OSTEOBLASTOGENESIS AND PROMOTION OF APOPTOSIS OF OSTEOBLASTS AND OSTECYTES BY GLUCOCORTICOIDS POTENTIAL MECHANISMS OF THEIR DELETERIOUS EFFECTS ON BONE", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 102, no. 02, 1 July 1998 (1998-07-01), US, pages 274 - 282, XP002925692, ISSN: 0021-9738, DOI: 10.1172/JCI2799 *
ZIEGLER R: "MEDIKAMENTOESE THERAPIE DER OSTEOPOROSE INTERESSANTE RESULTATE MIT BISPHOSPHONATENÜ", TW-GYNAEKOLOGIE, KARLSRUHE, DE, vol. 5, no. 2, 1992, pages 140,142 - 144,146, XP000904961, ISSN: 0935-3208 *

Also Published As

Publication number Publication date
AU1525700A (en) 2000-06-05
US6416737B1 (en) 2002-07-09
WO2000028982A2 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
WO2000028982A3 (en) Increasing bone strength with selected bisphosphonates
CY1119153T1 (en) FROM ORAL DEFECTED DISCS
SE9901272D0 (en) New improved formulation
WO2000002905A3 (en) Methods for accelerating bone and cartilage growth and repair
AU2003300898A1 (en) Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
CA2279846A1 (en) Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
SE9703691D0 (en) Pharmaceutical compositions
CY1107810T1 (en) COMPOSITIONS WHICH HAVE A COMBINATION OF IMMEDIATE LIBERATION AND CONTROLLED LIBERTY CHARACTERISTICS
ATE258813T1 (en) DEVICE FOR THE DOSED INHALATION OF BECLOMETHASONE DIPROPRIONATE
AU6513701A (en) Compositions and methods for identifying agents which modulate pten function andpi-3 kinase pathways
EP1075536A4 (en) Methods for identifying pathways of drug action
EP1666092A3 (en) Drug combination comprising a fatty acid and a uridine compound.
BR0209875A (en) Dental Restoration Materials
ATE323214T1 (en) REDUCTION OF MINERAL SALT DEPOSITION
WO1998057620A3 (en) Inositol for modulation of immune response
DE69814979D1 (en) Blood lipoprotein regulating preparation
WO2003088904A3 (en) Screening and therapeutic methods for treating circadian rhythm disorders
PT978284E (en) Use of 15-keto-prostaglandin-e compounds as endothelin antagonists
CA2316014A1 (en) Brake disc wear indicator
FR2767829B1 (en) ACRYLIC OR METHACRYLIC PHOSPHONATE OR GEM-BISPHOSPHONATE COMPOUNDS
CA2286752A1 (en) Implant system
DE60029937D1 (en) ANGIOTENSIN II AND ANALOGUE FOR THE LIMITATION OF SCARS AND ADHESION FORMATION
ATE419346T1 (en) INHIBITION OF THE FORMATION OF ATHEROSCLEROTIC WOUNDS USING AFABP ANTISENS NUCLEIC ACIDS
AU651658B2 (en) Phosphatidylinositol analogues, inhibitors of phosphatidylinositol - specific phospholipase C
PL1711507T3 (en) Crystalline form of risedronate monosodium

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 15257

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase